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Abstract
Background
Infants born to dengue immune mothers acquire maternal antibodies to dengue. These anti-
bodies, though initially protective, decline during the first year of life to levels thought to be
disease enhancing, before reaching undetectable levels. Infants have long been studied to
understand the interaction between infection and disease on an individual level.
Methods/Findings
Considering infants (cases <1 year old) as a unique group, we analyzed serotype specific
dengue case data from patients admitted to a pediatric hospital in Bangkok, Thailand. We
show differences in the propensity of serotypes to cause disease in individuals with dengue
antibodies (infants and post-primary cases) and in individuals without dengue antibodies
(primary cases). The mean age of infant cases differed among serotypes, consistent with
previously observed differential waning of maternal antibody titers by serotype. We show
that trends over time in epidemiology of infant cases are consistent with those observed in
the whole population, and therefore with trends in the force of infection.
Conclusions/Significance
Infants with dengue are informative about the interaction between antibody and the dengue
serotypes, confirming that in this population DENV-2 and DENV-4 almost exclusively cause
disease in the presence of dengue antibody despite infections occurring in others. We also
observe differences between the serotypes in the mean age in infant cases, informative
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about the interaction between waning immunity and disease for the different serotypes in
infants. In addition, we show that the mean age of infant cases over time is informative
about transmission in the whole population. Therefore, ongoing surveillance for dengue in
infants could provide useful insights into dengue epidemiology, particularly after the intro-
duction of a dengue vaccine targeting adults and older children.
Author Summary
Infants born to dengue immune mothers acquire maternal dengue antibodies. These anti-
bodies, though initially protective, decline during the first year of life to levels thought to
be disease enhancing, before reaching undetectable levels. We show that in this popula-
tion, DENV-2 and DENV-4 almost exclusively cause disease in the presence of dengue
antibody, despite infections occurring in others. We also observe serotype-specificity in
the mean age of infant cases, consistent with differential waning of antibody to each sero-
type. These results highlight serotype-specificity in the way the immune response interacts
with infection to cause disease. In addition, we show that the mean age of infant cases over
time is informative about transmission in the whole population. Therefore, ongoing sur-
veillance for dengue in infants could provide useful insights into dengue epidemiology,
particularly after the introduction of a dengue vaccine targeting adults and older children.
Introduction
DENV is a flavivirus that exists as four serotypes. Infection with one serotype leads to long-
term immunity to that serotype. There is also a short-term period of cross-protection to other
serotypes [1, 2] followed by an indeterminate period during which infection by another sero-
type may lead to more severe disease [3]. One theory for this increased severity is antibody
dependent enhancement, whereby non-neutralizing antibodies bind to the virus and facilitate
viral entry into cells and increased viral replication [4]. The overwhelming majority of hospital-
ized cases in regions where all four serotypes circulate are due to post-primary infections [5].
Infants born to dengue-immune mothers receive dengue antibodies, and, over the first year of
life, experience an accelerated version of the susceptibility pattern that individuals experience
during a lifetime in endemic areas: there is a short period of universal protection lasting a few
months after birth, followed by a period also lasting a few months in which infections are more
likely to be severe possibly through the action of antibody dependent enhancement [6].
Infant cases of dengue have been an important group for studying dengue immunopatho-
genesis. Previous studies have described the disease presentation and age distributions of
infants in Thailand, Vietnam, Indonesia and the Philippines [7–9], as well as considering the
interaction between antibody titres and disease [6, 10–12]. Infant cases may also be an impor-
tant group for understanding other aspects of the epidemiology of dengue at population scales.
There are two main advantages to evaluating infant cases for studying the interaction between
immunity and disease. First, at a population scale and even at individual scales, infants have
fairly uniform antibody titers across serotypes and, thus, eliminate the uncertainty of timing
and nature of past exposures that exists when considering serotype differences in disease sever-
ity among older children. Second, the time period that infants are at high risk of infection with
severe outcome is relatively short, thus providing information on forces of infection in the pop-
ulation at this time.
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In the current study, we analyzed dengue case data from Queen Sirikit National Institute of
Child Health (QSNICH) from 1973–2012 to investigate dengue in infants (cases<1 year old).
We sought to elucidate intrinsic differences in the propensity for different DENV serotypes to
cause disease among patients with pre-existing antibodies by examining serotype distributions
in hospitalized infants, compared to other age and immunity groups. We also examined possi-
ble relationships between antibody levels and disease outcome by examining the age of severe
cases among infants. Finally, we considered changes in dengue case numbers and mean age of
infant cases over time and what these changes revealed about the force of infection (FOI) of
dengue and population level transmission. This work is important for the study of dengue
pathogenesis and epidemiology and is particularly relevant to the development of vaccines. An
understanding of potentially protective antibody titers could inform vaccine immunogenicity
targets and could clarify the interactions among serotype, immunity and disease outcome
when interpreting population level vaccine trial results. Since no vaccine approaching licensure
currently plans to target those under 1 year of age, this group could also be an important
resource in Phase 4 studies as they will be easily identified as non-vaccinees, and can be used to
characterize indirect effects of vaccine campaigns as well as characterize temporal patterns in
population level transmission after the introduction of vaccines.
Materials and Methods
Study Design
The analyzed data were obtained from public health samples collected during passive surveil-
lance of hospitalized dengue cases from 1973 to 2012 at QSNICH, a 420-bed tertiary care pedi-
atric hospital located in Bangkok, Thailand, that serves as a Thailand Ministry of Public Health
(MOPH) dengue referral center for Bangkok. Ninety-nine percent of the dengue cases were
15 years of age. Acute and convalescent blood samples from clinically suspected dengue inpa-
tients at QSNICH were tested for evidence of DENV infection at the Armed Forces Research
Institute of Medical Sciences (AFRIMS) laboratory in Bangkok. The case data up until 1999
have been presented previously [13] and an updated analysis is in submission (Nisalak et al.,
submitted to AJTMH). Techniques used for measuring antibody titers and detecting virus have
changed over the years (see [13] Table 2). In brief, acute blood samples were tested by viral iso-
lation and/or hemi-nested reverse transcriptase polymerase chain reaction (RT-PCR) as previ-
ously described [14–18]. Acute and convalescent blood samples were tested by dengue
serological assays as previously described [19–22]. Primary infection refers to the first DENV
infection in an individual and was determined serologically by dengue hemagglutination inhi-
bition assay (HAI) and/or dengue IgM/IgG capture enzyme-linked immunosorbent assay
(ELISA) according to published criteria [22]. Post-primary infection refers to any DENV infec-
tion subsequent to primary infection and was also determined serologically [22]. The retrieval
and analysis of coded pre-existing data in this study was approved by the QSNICH and Walter
Reed Army Institute of Research Institutional Review Boards. Blood samples from passive sur-
veillance were originally collected at QSNICH for public health purposes. All data analyzed
were anonymized.
Statistical Analysis
For the purpose of this analysis, cases were grouped into three groups: 1) primary cases aged
less than 1 year old, which we refer to as infant primary cases, 2) primary cases aged1 year
old which we refer to as non-infant primary cases, and 3) post-primary cases of all ages. Only
40 of 21,090 post-primary cases were<1 year of age; these cases were included in the post-pri-
mary group, but their inclusion in this or the infant primary group did not alter the results. For
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each group, we calculated the proportion of cases that were of each serotype, and for each sero-
type, the proportion of cases that were in each group. Using Pearson correlations, the correla-
tion between the annual numbers of cases in each group for each serotype was assessed.
For infant primary cases, we calculated the mean age for cases of each serotype over all years
and the mean age for all serotypes for each year. Using generalized linear models, we assessed
trends over time and the relationship between annual mean age and annual proportion of all
cases in infants. Analysis was performed using R version 3.0.2 (R Foundation for Statistical
Computing, Vienna, Austria) [23].
Results
The serotype distribution in primary infant cases was more similar to the post-primary cases
than to primary cases in non-infants (Table 1 and Fig 1). For both post-primary and infant pri-
mary cases, around 35% of cases were DENV-1 and and 31% of cases were DENV-2. This is
significantly different to primary non-infant cases where a much greater 57% of cases were
DENV-1 and only 5% were DENV-2. For DENV-3 there are slight, non-significant differences
between post-primary and infant primary with 22% of post-primary and 27% of primary infant
cases due to DENV-3, and these are both significantly less than the 37% of primary non-infant
cases that were due to DENV-3. For DENV-4 there are significant differences across all 3
groups with 12% of post-primary cases, 4% of infant primary cases and only 1% of primary
non-infant cases due to DENV-4 (Table 1 and Fig 1). Although disease was still more common
in post-primary compared to primary cases for DENV-1 and DENV-3 (73% of cases were
post-primary), primary infections with these two serotypes caused a substantial amount of
Table 1. Proportion of serotyped cases in each group (primary in non-infants, primary in infants, and post-primary) for each serotype.
Group DENV-1 DENV-2 DENV-3 DENV-4 Total
Primary in non- infants 0.57 0.05 0.37 0.01 1
[0.55, 0.60] [0.02, 0.07] [0.34, 0.39] [0, 0.04] (1734)
(990) (83) (639) (22)
Primary in Infants 0.37 0.32 0.27 0.04 1
[0.34, 0.42] [0.27, 0.36] [0.23, 0.31] [0, 0.09] (632)
(238) (198) (170) (26)
Post-primary 0.35 0.31 0.22 0.12 1
[0.33, 0.36] [0.30, 0.32] [0.21, 0.24] [0.11, 0.13] (9717)
(3356) (3014) (2210) (1137)
Table shows proportion and 95% multinomial conﬁdence intervals in square brackets. Case numbers are in parentheses. The accompanying ﬁgure, with
the data by year, is Fig 1.
doi:10.1371/journal.pntd.0004262.t001
Table 2. Proportion of cases of each serotype that are in each group (primary in non-infants, primary in infants, and post-primary).
Group DENV-1 DENV-2 DENV-3 DENV-4 untyped
Primary in non-infants 0.22 (990) 0.02 (83) 0.21 (639) 0.02 (22) 0.09 (1151)
Primary in infants 0.05 (238) 0.06 (198) 0.06 (170) 0.02 (26) 0.03 (428)
Post-primary 0.73 (3356) 0.92 (3014) 0.73 (2210) 0.96 (1137) 0.88 (11373)
Total 1 (4584) 1 (3295) 1 (3019) 1 (1185) 1 (12952)
Table shows proportions of cases in each group that are of each serotype. Case numbers are in brackets. The accompanying ﬁgure, with the data by
year, is Fig 2.
doi:10.1371/journal.pntd.0004262.t002
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disease in dengue naïve individuals. For DENV-2 and DENV-4 however, almost all of the cases
of these serotypes were post-primary cases (92% and 96%, respectively). The percentage of
cases that were untyped was the same for the primary infant and non-infant cases (both 40%),
compared to post-primary cases (53%) (Table 2 and Fig 2).
There were positive, significant correlations within each serotype each year between the
number of infant primary cases, non-infant primary cases, and post-primary cases in each
year, i.e., the number of primary non-infant cases of a serotype each year was associated with
the number of infant primary cases and, separately, associated with the number of post-pri-
mary cases of that serotype each year (see Fig 2 and Table 3). For DENV-1 and DENV-3, the
correlations between the numbers in each group were between 0.78 and 0.95, while for DENV-
2 and DENV-4, these correlations were lower between 0.40 and 0.60.
Finally, we considered the trends over time in the mean age of infant primary cases and the
infant primary cases as a proportion of all cases (Fig 4). There was a significant positive correla-
tion between mean age and year (correlation 0.31, p-value:< 0.05). This increase in mean age
was clear from 1990 to around 2007, but there was a suggestion of a decrease after 2007. Age
distributions by decade are shown in Fig 3B. Using a linear model, there was a significant
Fig 1. Figures show the serotype distributions of primary cases in 1) primary cases in non-infants, 2)
infant cases and 3) post-primary cases. Serotypes DENV-1 to -4 are in purple, red, green and blue,
respectively, untyped is in yellow.
doi:10.1371/journal.pntd.0004262.g001
Fig 2. Each figure shows for each serotype individually (A-D: DENV-1 to -4) the number of primary
cases in infants, the number of primary cases in non-infants, and the number of post-primary cases
each year.Cases are shown on a log10 scale. Primary cases in infants are in dark blue, post-primary cases
are in mid blue, and primary cases in non-infants are in light blue.
doi:10.1371/journal.pntd.0004262.g002
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relationship between proportion of cases that were in infants and the mean age, year and the
interaction between mean age and year (p-values all<0.01, coefficients: mean age: 18, year:
0.005 and mean ageyear: -0.009). This relationship showed that during the years of increasing
mean age of infant cases (1990–2007), there was a decrease in the proportion of all cases that
were in infants; and during the years of decreasing mean age (after 2007), there was an increase
in the proportion of cases that were in infants (Fig 4).
Discussion
The serotype distributions of hospitalized dengue cases in different immune groups, as pre-
sented in this paper, add to the evidence that differences in the outcome of infection by each
serotype depends on immune status. The paucity of primary cases of DENV-2 and DENV-4
has been shown in previous studies in Thailand [5]. The presence of infant primary cases with
these serotypes, suggests that dengue naive individuals1 year of age are exposed to these
serotypes, but that these exposures do not result in hospitalized disease. There are two non-
mutually exclusive ways to interpret these findings: (1) DENV-1 and DENV-3 were more likely
to cause disease in non-immune individuals compared to DENV-2 and DENV-4, or (2)
DENV-2 and DENV-4 were more likely to cause disease in an enhanced post-primary infec-
tion than DENV-1 and DENV-3. These results from the infants suggest that the former is the
most likely explanation, with the correlations between the annual case numbers in each group
(infant primary, primary non-infant and post-primary) being lower for DENV-2 and DENV-
4, than for DENV-1 and DENV-3, suggesting the immune status of the population plays a
Table 3. Correlations between the case numbers of each serotype in each immune group each year,
p-values are shown in brackets.
Correlations between annual case numbers of (p-values)
Serotype Infants and primary Primary and post-primary Infants and post-primary
1 0.84 (<0.001) 0.91 (<0.001) 0.78 (<0.001)
2 0.60 (<0.001) 0.51 (<0.001) 0.60 (<0.001)
3 0.87 (<0.001) 0.94 (<0.001) 0.79 (<0.001)
4 0.40 (<0.05) 0.46 (<0.005) 0.60 (<0.001)
The mean age of all infant primary cases was just under 7 months (6.7 months [95% CI: 6.6, 6.9 months]).
Age distributions by serotype are shown in Fig 3A. The mean age was highest for DENV-1 and DENV-3
(both 7.3 months [95% CI: 6.9, 7.5 months]), with DENV-2 slightly lower (6.7 months [95% CI: 6.5, 7
months]) and DENV-4 the lowest (5.7 months, though with the widest CIs [95% CI: 5, 6.5 months]).
doi:10.1371/journal.pntd.0004262.t003
Fig 3. Figures show: A) number of cases in eachmonth age group by serotype over all years, B)
number of cases in eachmonth age group by decade over all serotypes.
doi:10.1371/journal.pntd.0004262.g003
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larger role in the dynamics of DENV-2 and DENV-4. These differences may also explain previ-
ously seemingly contradictory results where a relationship was shown between infant DHF and
increased levels of enhancing activity in sera for DENV2 [6], but not DENV3 [10]. In addition,
there is a suggestion that DENV-4 is under represented in the infant primary cases compared
to the secondary cases. This could be explained by a lower force of infection for DENV-4 (con-
sistent with the fewer observed cases) leading to fewer exposures in this early time period. Dif-
ferences between the serotypes in the propensity to cause disease in immune and non-immune
individuals should be considered in the context of vaccination trial results with seemingly dif-
ferential efficacy across serotypes, as with the Sanofi Phase 2b results [24]. Could the observed
effect of the vaccination for DENV2 be because of the differential outcomes of DENV2 expo-
sure in naïve and non-naïve individuals?
The mean age of infant primary cases was similar to previous studies [7, 8]. The observed
differences in the mean age in infants by serotype (highest for DENV-1 and DENV-3 followed
by DENV-2 then DENV-4) could be due to two non-mutually exclusive reasons. Firstly, the
force of infection could have been higher for the serotypes with the lower mean ages (so infec-
tions occurred on average earlier). Secondly, differential waning of antibody titers by serotype
could lead to potential enhancement occuring at different ages for the different serotypes. The
first explanation would suggest a higher force of infection for DENV-2 and DENV-4 compared
to DENV-1 and DENV-3. Previous work has suggested R0 and thus the FOI may be higher for
DENV-2 and the considerable numbers of DENV-2 cases [25] would be consistent with a high
FOI for DENV-2. However, DENV-4 had lower incidence overall and serological studies do
not suggest that DENV-4 has a higher R0 than other serotypes [25]. For antibody waning, pre-
vious work by van Panhuis et al. [26] indicated the fastest antibody waning to be for DENV-4
(with a mean titer at 6 months of 17 [95% CI: 12, 25]). The next fastest waning serotype was
DENV-2 (with a mean titre at 6 months of 25 (95% CI: 21, 31), followed by DENV-3 and
DENV-1 (mean titer at 6 months of 35 (95% CI: 29, 43)). This order of antibody waning is con-
sistent with the observed serotype-specific infant mean ages, though these results may be spe-
cific to the assays performed. There could, of course, also be differences between the serotypes
in the antibody response required for protection or to lead to enhanced infections, as observed
Fig 4. Figures show: 1) Absolute number of infant primary cases, 2) proportion of all cases that were
in infants, and 3) the mean age of infant primary cases (in months).
doi:10.1371/journal.pntd.0004262.g004
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in older individuals in a study in Kamphaeng Phet, Thailand [27]. With a population such as
Bangkok, we would expect broad antibody responses in maternal antibody, however further
study of maternal over time and in multiple populations would be of great interest.
The small but significant increase in mean age of infant cases over time (particularly in the
1990s to 2007) is consistent with the increase in mean age of dengue seen in the general popula-
tion in Thailand [28]. One of the leading hypotheses for this increase is a reduction in the force
of infection [28]. Both the trends in mean age of infant primary cases and the relative propor-
tion of all cases that were in infants, are consistent with a decrease in FOI during this period (as
the FOI drops we would expect to see fewer cases in infants as the chance of being infected in
this first year of life drops). It is interesting that after 2007, a decrease in the mean age of infant
cases, and an increase in the proportion of cases that were in infants was observed, suggesting
an increase in FOI in this period. This decrease in mean age was also observed in primary cases
of older age groups (Nisalak et al., submitted to AJTMH). Further years of data will be needed
to determine whether this a persistent trend or a transient fluctation. We show a change in the
mean age of infants over time and by serotype, however the numbers of cases in each year are
too small to determine the changes over time for each serotype.
Our study suggests that infants, in addition to being informative about immune-mediated
pathogenesis, could act as a sentinel population for understanding population-level transmis-
sion. Vaccines currently in development are unlikely to be given to infants [29, 30], and there-
fore, this age group will still be largely susceptible to infection even after vaccine introduction.
With this lack of change in susceptibility, surveillance of this population could help determine
whether transmission or simply disease presentation has altered due to vaccination. Whether
infant susceptibility changes due to vaccine-derived maternal immunity will also be an impor-
tant question to address in follow up studies. One would hope that ultimately, infants will be
protected by herd immunity, however, if protection is suboptimal for some serotypes, is greater
against severe disease as opposed to just infection, or vaccine coverage is low, the force of infec-
tion could be maintained at close to pre-vaccination levels. Therefore, infants will still be at
substantial risk for infection and be an important population to observe to understand immu-
nity and transmission.
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